RECHERCHE :   Cancers digestifs
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
AMGEN 20120139: A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
Tous les types de tumeurs
registre
CHUV
AMGEN 20140318 - T-VEC intrahepatic: A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab
Tumeur du foie non opérable (HCC) ou non-HCC
I, II
CHUV, HUG
BP40234: An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of RO6874281, an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors
Tumeurs solides (ORL, œsophage, col de l'utérus)
II
CHUV, HUG
DANTE: A randomized, open-label Phase II efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction.
Gastric cancer and adenocarcinoma of the oesophago-gastric junction
II
HUG
DCC-2618-03-002 Intrigue: A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
Advanced Gastrointestinal Stromal tumor
III
CHUV
EORTC 1560 ILOC study: Phase II of immunotherapy plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with colorectal cancer liver metastases:
Colorectal cancer liver metastasis
II
HUG
INNOVATION: INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer
Cancer de l'estomac HER-2 positif
II
CHUV, HUG
MK3475-937: A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation
Hepatocellular carcinoma after surgical resection
III
CHUV, HUG
CO39612_MORPHEUS CRC: A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic colorectal cancer.
Cancer coloréctal métastatique
I, II
CHUV
PEMREC:A Phase II Study to Evaluate Safety and Efficacy of Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
Localised MSS Rectal Cancer
II
HUG
PRODIGE 32: Systematic surgery vs. monitoring and salvage surgery in operable oesophageal cancer in complete clinical response after chemoradiation. Strategic multicenter randomised phase II-III trial
Cancer de l'oesophage
II, III
HUG
RACIN, A phase I study of the combination of nivolumab associated with low-dose radiation, aspirin/ celecoxib and either ipilimumab or low-dose cyclophosphamide, followed by nivolumab maintenance, in patients with advanced, TIL-negative solid tumors
Tumeurs solides
I
CHUV
SAKK 41/13: Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial.
Cancer du côlon PIK3CA muté
III
CHUV, HUG
SAKK 41/14: Physical activity program in patients with metastatic colorectal cancer who receive palliative first-line chemotherapy. A multicenter open label randomized controlled phase III trial
Activité physique chez des patients recevant une chimiothérapie pour un cancer colorectal
III
HUG
CHUV-DO-0012-SolTIL-2018 - Phase Ib Study To Assess The Feasibility And Safety Of Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes In Advanced Solid Tumors
Tumeurs solides
I
CHUV
AMGEN 20140299 - T-VEC Breast-Colorectal: A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Cancer du sein métastatique triplement négatif ou cancer colorectal avec métastases hépatiques
I
HUG